[Lipid-lowering drugs].
Accumulating evidences in recent major clinical studies have shown the importance of anti-hyperlipidemic treatment in preventing atherosclerotic cardiovascular diseases. Lipid-lowering drugs can be divided into HMG-CoA reductase inhibitors (statins), bile-acid sequestrants (resins), nicotinic acid, fibrates and probucol. Among them, statins had revolutionary impact on the treatment of hyperlipidemia since pravastatin, which was developed in Japan, was launched in 1989. Several lipid-lowering drugs are now under development in Japan, including pitavastatin, rosuvastatin, F-1394 (ACAT inhibitor), CS-505 (ACAT inhibitor) and NO-1886 (LPL activator). In this review, characteristics of these new lipid-lowering drugs will be discussed.
Hirakawa
Y
Y
Department of Cardiovascular Medicine, Kyushu University Graduate School of Medical Sciences, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.
Shimokawa
H
H
D001549:Benzamides; D003510:Cyclohexanes; D004146:Dioxanes; D015195:Drug Design; D004791:Enzyme Inhibitors; D005464:Fluorobenzenes; D015248:Gemfibrozil; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents / Q000145:classification; D007564:Japan; D009943:Organophosphorus Compounds; D011743:Pyrimidines; D011804:Quinolines; D000068718:Rosuvastatin Calcium; D002785:Sterol O-Acyltransferase / Q000037:antagonists & inhibitors; D013449:Sulfonamides
D001549:Benzamides; D003510:Cyclohexanes; D004146:Dioxanes; D004791:Enzyme Inhibitors; C094918:F 1394; D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D009943:Organophosphorus Compounds; D011743:Pyrimidines; D011804:Quinolines; D013449:Sulfonamides; C082137:4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide; D000068718:Rosuvastatin Calcium; D002785:Sterol O-Acyltransferase; C108475:pitavastatin; D015248:Gemfibrozil